sorafenib has been researched along with deoxyglucose in 5 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (deoxyglucose) | Trials (deoxyglucose) | Recent Studies (post-2010) (deoxyglucose) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 11,426 | 171 | 1,375 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barba, M; Bernardini, C; Castellini, L; Gasbarrini, A; Maulucci, G; Pani, G; Piscaglia, AC; Pontoglio, A; Puglisi, MA; Samengo, D; Scatena, R; Spelbrink, JN; Tesori, V | 1 |
| Cheng, SP; Chuang, JH; Lin, LL; Shieh, DB; Wang, PW; Wang, SY; Wei, YH | 1 |
| Garcia-Manero, G; Hu, Y; Huang, A; Huang, P; Ju, HQ; Liu, D; Liu, K; Wen, S; Zhan, G | 1 |
| Ghoshal, K; Jacob, ST; Motiwala, T; Reyes, R; Wani, NA | 1 |
| Garcia-Manero, G; Hu, Y; Huang, A; Huang, P; Ju, HQ; Li, J; Li, Y; Lu, WH; Sun, Y; Wen, S; Xu, RH; Yang, J; Zhan, G | 1 |
5 other study(ies) available for sorafenib and deoxyglucose
| Article | Year |
|---|---|
The multikinase inhibitor Sorafenib enhances glycolysis and synergizes with glycolysis blockade for cancer cell killing.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Cell Respiration; Cell Survival; Deoxyglucose; Energy Metabolism; Glycolysis; Mitochondria; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Reactive Oxygen Species; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases | 2015 |
2-Deoxy-d-Glucose Can Complement Doxorubicin and Sorafenib to Suppress the Growth of Papillary Thyroid Carcinoma Cells.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxyglucose; Dose-Response Relationship, Drug; Doxorubicin; Drug Combinations; Drug Synergism; Gene Expression; Glycolysis; Humans; Lactic Acid; Mutation; Niacinamide; Oxygen Consumption; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Sorafenib; Thyroid Gland | 2015 |
Metabolic alterations and drug sensitivity of tyrosine kinase inhibitor resistant leukemia cells with a FLT3/ITD mutation.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxyglucose; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; G2 Phase Cell Cycle Checkpoints; Genetic Predisposition to Disease; Glycolysis; Humans; Leukemia, Myeloid, Acute; Mice; Mitochondria; Mutation; Niacinamide; Phenotype; Phenylurea Compounds; Protein Kinase Inhibitors; Pyruvates; Signal Transduction; Sorafenib; Tandem Repeat Sequences; Time Factors | 2016 |
Sorafenib and 2-Deoxyglucose Synergistically Inhibit Proliferation of Both Sorafenib-Sensitive and -Resistant HCC Cells by Inhibiting ATP Production.
Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxyglucose; Drug Synergism; G1 Phase; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Resting Phase, Cell Cycle; Sorafenib | 2017 |
ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Cell Line; Cell Transformation, Neoplastic; Deoxyglucose; fms-Like Tyrosine Kinase 3; Glycolysis; Hematopoietic Stem Cells; Hexokinase; Humans; Hydrocarbons, Brominated; Leukemia, Experimental; Mice; Mice, Inbred BALB C; Microsatellite Repeats; Mitochondria; Molecular Targeted Therapy; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Propionates; Proto-Oncogene Proteins c-akt; Sorafenib | 2017 |